Metrics as of 10/13/2026, 06:33 PM (Berlin time), refresh in progress.
Vera Therapeutics Stock
Vera Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Marshall Fordyce
- Employees
- 361
- Market cap
- $1.9 B
- IPO
- 14/05/2021
- Web
- veratx.com
Vera Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Brisbane, California, within the United States. The organization focuses on the development and commercialization of treatments for significant immunological disorders, with its primary market being the United States. Founded in 2016,…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Vera Therapeutics stock: price history
1D
-3.4%
1W
-8.9%
1M
-23.6%
6M
-39.6%
YTD
-47.1%
1Y
-12.1%
2Y
-37.3%
5Y
+75.0%
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~18% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 12/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Vera Therapeutics
Analyst assessment of Vera Therapeutics
PRICE TARGET LOW
US$34.00
CONSENSUS
US$80.89
MEDIAN
US$84.00
PRICE TARGET HIGH
US$125.00
1
STRONG BUY
12
BUY
1
HOLD
0
SELL
0
STRONG SELL
14
TOTAL · Buy
As of: 08/09/2026
Vera Therapeutics stock metrics
P/E
-4.57
P/B
4.72
EV/EBITDA
-4.95
RETURN ON EQUITY
-26.8%
NET MARGIN
0.0%
DEBT/EQUITY
0.18
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
81.5%
FLOAT SHARES
58,512,538
AVG. DAILY VOLUME (30D)
2,379,396
Insider transactions (SEC)
Fordyce Marshall
Fordyce Marshall
Young Joseph R
Fordyce Marshall
Fordyce Marshall
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -3.4%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Vera Therapeutics stock
What does Vera Therapeutics do?
Vera Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Marshall Fordyce, the company employs around 361 people.
The IPO was on 14/05/2021; the stock trades on NASDAQ under the ticker VERA.
What do analysts say about Vera Therapeutics stock?
14 analysts rate the stock, the consensus is Buy (as of 08/09/2026).
The average price target is US$80.89, ranging from US$34.00 to US$125.00, with a median of US$84.00.
This is an external assessment, not a statement by Market Jury.
When does Vera Therapeutics report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly -18% stronger than usual.
Does Vera Therapeutics pay a dividend?
No, Vera Therapeutics currently does not pay a dividend.
Which stocks are comparable to Vera Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Vera Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Vera Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.